/PRNewswire/ AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab.
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) - read this article along with other careers information, tips and advice on BioSpace
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ AbbVie today announced new data on the investigational use of risankizumab in Crohn s disease, upadacitinib in ulcerative colitis and. | October 3, 2021
AbbVie today announced new data on the investigational use of risankizumab in Crohn's disease, upadacitinib in ulcerative colitis and HUMIRA ® in inflammatory bowel disease will be presented as live presentations and e-Posters at the United European Gastroenterology Week Virtual 2021, to be held October 3-5 . AbbVie is presenting a total of 13 abstracts, across a broad range of studies in IBD, including two .